ARAY ACCURAY INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1138723 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-12.5%
TTM net income YoY10.0%
TTM EPS YoY22.0%
Revenue 3-yr CAGR-4.6%
Net income 3-yr CAGR—
Margins
Gross margin28.0%
Operating margin-13.1%
Net margin-4.4%
FCF margin-6.9%
EBITDA margin-11.2%
Returns
ROE-30.2%
ROA-4.1%
ROIC (approx.)-32.5%
Asset turnover0.93x
Leverage & solvency
Liabilities / assets86.4%
Debt / equity1.91x
Current ratio1.56x
Interest coverage-1.41x
Cash quality & payout
Operating cash flow / net income1.32x
Accruals ratio1.3%
Payout ratio—
Capex / revenue1.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q32026-03-31 | 2026Q22025-12-31 | 2025Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q32025-03-31 | 2025Q22024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $86.52M | $100.92M | $104.84M | $102.24M | $93.94M | $127.54M | $113.24M | $116.17M |
| Cost of revenue | $60.44M | $65.84M | $79.55M | $78.17M | $66.93M | $88.56M | $81.62M | $74.28M |
| Gross profit | $26.08M | $35.08M | $25.29M | $24.07M | $27.01M | $38.98M | $31.63M | $41.89M |
| R&D expense | $7.81M | $7.71M | $8.18M | $10.65M | $11.22M | $11.47M | $10.71M | $13.64M |
| SG&A expense | $10.32M | $11.51M | $11.22M | $10.06M | $12.60M | $11.87M | $10.76M | $12.43M |
| Operating income | -$36.50M | $5.52M | -$9.09M | -$11.57M | -$11.31M | $4.23M | $1.05M | $4.71M |
| Interest expense | $11.83M | $8.70M | $8.45M | $7.71M | $8.05M | $4.23M | $2.89M | $2.88M |
| Pretax income | $10.65M | -$1.51M | -$11.34M | -$13.20M | -$21.21M | $2.07M | -$840,000 | $3.23M |
| Income tax | $517,000 | $434,000 | $468,000 | $573,000 | $471,000 | $948,000 | $457,000 | $695,000 |
| Net income | $10.13M | -$1.94M | -$11.80M | -$13.77M | -$21.68M | $1.12M | -$1.30M | $2.54M |
| EBITDA | -$34.48M | $7.55M | -$7.39M | -$9.77M | -$9.64M | $5.83M | $2.55M | $6.21M |
| EPS (basic) | 0.07 | — | -0.09 | -0.11 | -0.18 | — | -0.01 | 0.03 |
| EPS (diluted) | 0.07 | — | — | -0.11 | -0.18 | — | -0.01 | 0.02 |
| Weighted avg. shares (diluted) | 139.26M | — | — | 120,973 | 118.95M | — | 102.83M | 103,746 |
| Banking | ||||||||
| Provision for credit losses | $0 | -$29,000 | -$61,000 | -$22,000 | $685,000 | -$147,000 | -$245,000 | $47,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $42.25M | $40.62M | $38.07M | $41.30M | $63.34M | $57.42M | $77.82M | $62.58M |
| Receivables | $50.34M | $67.41M | $64.57M | $60.96M | $54.38M | $83.19M | $78.19M | $87.28M |
| Inventory | $146.08M | $147.07M | $156.63M | $150.96M | $155.50M | $141.02M | $146.44M | $148.83M |
| Current assets | $266.05M | $287.78M | $293.22M | $292.39M | $303.60M | $317.46M | $333.46M | $325.89M |
| PP&E, net | $25.92M | $27.32M | $29.00M | $29.26M | $29.01M | $28.66M | $27.08M | $26.88M |
| Goodwill | $22.52M | $57.91M | $57.88M | $57.85M | $57.91M | $57.80M | $57.72M | $57.67M |
| Intangibles | — | $0 | — | $1,000 | $4,000 | $15,000 | $26,000 | $37,000 |
| Total assets | $390.06M | $443.68M | $447.60M | $448.01M | $456.82M | $470.24M | $484.29M | $478.38M |
| Current liabilities | $170.11M | $191.41M | $205.84M | $199.44M | $194.61M | $192.58M | $203.43M | $201.45M |
| Short-term debt | $6.70M | $1.50M | $11.16M | $11.11M | $12.85M | $12.73M | $7.57M | $7.56M |
| Long-term debt | $94.97M | $146.37M | $134.02M | $124.78M | $127.32M | $123.79M | $166.21M | $167.95M |
| Total debt | $101.67M | $147.87M | $145.18M | $135.89M | $140.17M | $136.52M | $173.78M | $175.51M |
| Total liabilities | $336.94M | $401.98M | $405.89M | $394.59M | $394.95M | $389.07M | $434.71M | $430.49M |
| Shareholders' equity | $53.12M | $41.70M | $41.71M | $53.42M | $61.87M | $81.17M | $49.58M | $47.89M |
| Net debt | $59.42M | $107.25M | $107.11M | $94.59M | $76.83M | $79.10M | $95.96M | $112.93M |
| Shares outstanding | 119.58M | 119.43M | 118.93M | 118.79M | 113.28M | 112.64M | 102.85M | 102.81M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.81M | $2.43M | -$5.60M | -$15.99M | $12.18M | -$9.71M | $18.06M | $1.80M |
| Capital expenditure | $124,000 | $461,000 | $471,000 | $3.02M | $1.90M | $1.32M | $958,000 | $874,000 |
| Free cash flow | -$3.94M | $1.97M | -$6.07M | -$19.01M | $10.28M | -$11.03M | $17.10M | $927,000 |
| Investing cash flow | -$5.00M | -$1.35M | -$1.51M | -$5.60M | -$3.82M | -$3.40M | -$2.43M | -$1.57M |
| Financing cash flow | $10.32M | $3.62M | $4.11M | -$282,000 | -$475,000 | -$5.84M | -$2.00M | $5.77M |
| Depreciation & amortization | $2.03M | $2.02M | $1.70M | $1.80M | $1.68M | $1.60M | $1.50M | $1.50M |
| Stock-based compensation | $1.12M | $1.68M | $1.38M | $881,000 | $2.52M | $2.82M | $2.75M | $2.28M |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.